Id: | acc4828 |
Group: | 1sens |
Protein: | AMPK |
Gene Symbol: | PRKAA1 |
Protein Id: | Q13131 |
Protein Name: | AAPK1_HUMAN |
PTM: | phosphorylation |
Site: | Thr183 |
Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
Disease Category: | Endocrine and metabolic diseases |
Disease: | Diabetes Mellitus |
Disease Subtype: | type 2 diabetes |
Disease Cellline: | |
Disease Info: | |
Drug: | metformin |
Drug Info: | "Metformin is a widely - used oral medication for treating type 2 diabetes, which helps control blood sugar levels." |
Effect: | modulate |
Effect Info: | "Analysis of AMPK phosphorylation levels revealed that AMPK activity in peripheral blood mononuclear cells (PBMCs) was decreased in patients with type 2 diabetes, and this effect was reversed by metformin again." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 35605453 |
Sentence Index: | 35605453_9 |
Sentence: | "Analysis of AMPK phosphorylation revealed that its activation was decreased in the PBMCs of type 2 diabetic patients, an effect which was reversed, once again, by metformin." |
Sequence & Structure:
MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACPRKAA1-Thr183 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.707 |
HGSC | -0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 183 | D | Colon cancer/carcinoma | Phosphorylation | 25679763 |
T | 183 | U | Breast cancer | Phosphorylation | 30413706 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.